Bevacizumab taxan Första linjens behandling vid metastaserande Her2- bröstcancer.

Slides:



Advertisements
Similar presentations
Take home message Breast Cancer Bevacizumab in MBC Sabino De Placido 1.
Advertisements

Miles DW et al. SABCS 2009;Abstract 41.
FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev
Integration of Taxanes in the Management of Breast Cancer
Oncologic Drugs Advisory Committee
Extending life for women with HER2-positive MBC
“Taking Care of Tomorrows Patient Better than Today”… the Future is Now Set A1 – Title Slide David O’Malley, M.D.
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
Which difference should we target? Alberto Sobrero Ospedale San Martino IRCCS Genova, Italy.
Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent trials settled the question of maintenance versus observation in advanced CRC? Yes Deborah Schrag,
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Metastatic Breast Cancer Dr. Christine Simmons, MD MSc FRCP(C) Medical Oncologist, St. Michael’s Hospital Assistant Professor, University of Toronto
Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.
Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
Drug Treatment of Metastatic Breast Cancer
AVADO PFS Analysis (ITT Population) All P values vs. placebo Adapted from Miles et al. ASCO 2008, abstract LBA 1011.
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial to Evaluate the Efficacy and Safety of Placebo + Trastuzumab + Docetaxel vs.
Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.
Bevacizumab: Antiangiogenic therapy for breast cancer: where do we stand? Fortunato Ciardiello Division of Medical Oncology, Department of Clinical and.
Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.
Il punto di vista del clinico Fabio Puglisi, MD PhD Ruolo della terapia antiangiogenica nel carcinoma mammario.
RIBBON-1: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy with or without Bevacizumab for First-Line Treatment of HER2-Negative.
A Meta-Analysis of Overall Survival Data from Three Randomized Trials of Bevacizumab (BV) and First-Line Chemotherapy as Treatment for Patients with Metastatic.
Use of Chemotherapeutic and Biologic Agents in Metastatic Breast Cancer Breast Cancer Update Medical Oncology Educational Forum May 21, 2005 Kathy D Miller.
Kathy D. Miller, MD Associate Professor and Sheila D. Ward Scholar Indiana University Melvin and Bren Simon Cancer Center Indianapolis, IN Advances in.
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
A Meta-Analysis of Overall Survival Data from Three Trials of Bevacizumab and First-Line Chemotherapy as Treatment for Patients with Metastatic Breast.
Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.
Assistant Professor of Medicine Dana-Farber Cancer Institute
Chemotherapy and Targeted Therapy for Metastatic Breast Cancer Part 1: HER 2 Negative Dr. Sonal Gandhi Sunnybrook Odette Cancer Centre March 18, 2011 Thanks.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib.
Locally advanced and metastatic disease
E2100 A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab as First- Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.
Pritchard KI et al. Proc SABCS 2010;Abstract P
RUOLO DELLA TERAPIA ANTIANGIOGENICA NEL CARCINOMA MAMMARIO Rilevanza delle Evidenze Scientifiche P Pronzato Modena,
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-
Taxanes — Taxanes are among the most active agents for metastatic breast cancer – Docetaxel, Paclitaxel, NabPaclitaxel. Anthracyclines – Doxorubicin, Epirubicin,
Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.
A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.
Pazopanib in Advanced Ovarian Cancer: A new galloping horse. Dr. Raafat Ragaie, MD,FRCR.
Y-K Kang, A Ohtsu, E Van Cutsem, SY Rha, A Sawaki SR Park, H-Y Lim, J Wu, B Langer, MA Shah on behalf of AVAGAST investigators AVAGAST: a randomized, double-blind.
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
CCO Independent Conference Highlights
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
Alessandra Gennari, MD PhD
Management of metastatic and recurrent head and neck cancer
Azienda Ospedaliero Universitaria Policlinico Modena
Chicago 2008: Post - ASCO Analysis: Metastatic Breast Cancer
Intention-to-treat population
Chieti, 27 Giugno 2016 Taxanes and bevacizumab are the standard first line theraphy for Her2-negative metastatic breast cancer Discussant Giorgio Mustacchi.
LOTUS: Investigation of Ipatasertib, a Novel Akt Inhibitor, in Combination With Paclitaxel as Frontline Therapy for Metastatic TNBC CCO Independent Conference.
The Evolving Standard of Care in Gastric Cancer
Final results of the phase III, randomised, double-blind AVOREN trial of first-line bevacizumab + interferon-a2a in metastatic renal cell carcinoma Escudier.
Bevacizumab in platinum-sensitive ovarian cancer: OCEANS.
Barrios C et al. SABCS 2009;Abstract 46.
Krop I et al. SABCS 2009;Abstract 5090.
A Report from ECCO 14 Oral Chemotherapy in Breast Cancer
Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011
Baselga J et al. SABCS 2009;Abstract 45.
First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line.
Lunedì 04 giugno Highlight a cura di Filippo de Marinis
Intervista a Filippo de Marinis
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
Presentation transcript:

Bevacizumab taxan Första linjens behandling vid metastaserande Her2- bröstcancer

3 randomiserade studier E2100 E2100 AVADO AVADO RIBBON 1 RIBBON 1 2 METAANALYSER 2 METAANALYSER

E patienter 722 patienter 90 mg paklitaxel/m2 dag 1, 8, 15 +/- bevacizumab 10 mg/kg dag 1, mg paklitaxel/m2 dag 1, 8, 15 +/- bevacizumab 10 mg/kg dag 1, 15 Primär endpoint: PFS Primär endpoint: PFS

Progressionsfri överlevnad

AVADO 736 patienter 736 patienter Docetaxel 100mg/m2 + placebo Docetaxel 100mg/m2 + placebo Docetaxel 100mg/m2 + bevacizumab 7,5 mg eller 15 mg qW 3 Docetaxel 100mg/m2 + bevacizumab 7,5 mg eller 15 mg qW 3

Bevacizumab 7.5mg/kg q3w + docetaxel (n=248) 9.0 AVADO: updated PFS 7.5mg dose PFS estimate Time (months) Placebo + docetaxel (n=241) Unstratified HR=0.86 (0.72–1.04), p=0.1163* 8.2 Intent-to-treat analysis; *p values are of exploratory nature ‡ censored for non-protocol therapy prior to progressive disease Stratified HR ‡ =0.80 (0.65–1.00), p=0.0450* 8.1

Bevacizumab 15mg/kg q3w + docetaxel (n=247) AVADO: updated PFS 15mg dose PFS estimate Time (months) Placebo + docetaxel (n=241) 10.1 Unstratified HR=0.77 (0.64–0.93), p=0.0061* 8.2 Intent-to-treat analysis; *p values are of exploratory nature ‡ censored for non-protocol therapy prior to progressive disease Stratified HR ‡ =0.67 (0.54–0.83), p=0.0002*

AVADO: updated efficacy ORR and 1-year survival Placebo + docetaxel Bev 7.5* + docetaxel Bev 15* + docetaxel Patients with measurable disease at baseline n=207n=201n=206 ORR, % Difference vs placebo p value vs placebo ‡ ‡ *mg/kg q3w ‡ p values are of exploratory nature ITT populationn=241n=248n=247 1-year survival rate, % Difference vs placebo p value vs placebo0.198 ‡ 0.02 ‡ Patients still at risk, n

RIBBON patienter 1237 patienter Bevacizumab 15 mg qW 3 gavs som tilläggsbehandling till capecitabin, taxan- eller anthracyklingbehandling Bevacizumab 15 mg qW 3 gavs som tilläggsbehandling till capecitabin, taxan- eller anthracyklingbehandling

Study Design Capecitabine (1000 mg/m 2 BID x 14d) Taxane (docetaxel q3w or protein-bound paclitaxel q3w) Anthracycline-based chemotherapy (AC, EC, FAC, FEC) Placebo or bevacizumab (15 mg/kg q3w) CHOICE OF CHEMO BY INVESTIGATOR Capecitabine or Taxane or Anthracyclin e Previously untreated MBC (n=1237) Stratification Factors: Disease-free interval Previous adjuvant chemotherapy Number of metastatic sites Cape, T or Anthra Chemo + bevacizumab q3w Chemo + placebo q3w Optional 2 nd -line Chemo + bevacizumab Treat until PD RANDOMIZE 2:1

Capecitabine: PFS by Investigator Median, mo HR (95% CI)0.69 (0.56–0.84) p-valuep= Median, mo HR (95% CI)0.68 (0.54–0.86) p-valuep= PL (n=206) BV (n=409) IRC INV

Taxane/Anthra: PFS by Investigator Median, mo HR (95% CI)0.64 (0.52–0.80) p-valuep< Median, mo HR (95% CI)0.77 (0.60–0.99) p-valuep=0.040 PL (n=207) BV (n=415) IRC INV

Analysis of PFS by stratification factors: Cape and T/Anthra Cohorts Analysis of PFS by stratification factors: Cape and T/Anthra Cohorts + BV better + PL better Baseline Factor Total n Hazard Ratio All Patients Disease-free interval (mo) ≤ > Number of metastatic sites < ≥ Prior adjuvant chemotherapy Yes No BV better + PL better Total n Hazard Ratio CapeT/Anthra

Objective Response Rate Measurable disease (n) Includes only patients with measurable disease at baseline Cape p= T/Anthra p= % BVPLBVPL

Metaanalys Lee et al

Metaanalys